The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
What are the main advances in patient care that we are seeing with novel agents for leukemia? #ASCO21
Featured:
Jorge CortesDuring the 2021 ASCO Annual Meeting, the ALL Hub spoke with Jorge Cortes, Augusta University, Augusta, US. We asked, What are the main advances in patient care that we are seeing with novel agents for leukemia?
What are the main advances in patient care that we are seeing with novel agents for leukemia?
Cortes begins by outlining two practice-changing trials and their encouraging response rates. The first being the ZUMA-3 (utilizing CAR T-cell therapy), and the second investigating lintuzumab regimes in adult Philadelphia chromosome-positive ALL patients. He goes on to review two further studies investigating inotuzumab and the value of assessing MRD in patients.